Zafgen Inks $33M Series C for Obesity Drug
Cambridge, Mass.-based pharmaceutical company Zafgen Inc., which is developing novel obesity therapeutics, has closed on $33 million in Series C financing. Existing shareholders are leading the round, including Atlas Venture and Third Rock Ventures. The money will help support development of Zafgen’s pipeline and to advance its lead treatment for severe obesity into Phase 2 clinical studies.
7 July 2011•5 mins read
